- 2014
- What's on? - 17.09.2014
September 21th 2014: World Alzheimer’s Day
Inserm has made Alzheimer’s disease one of its priorities. Each year, this neurodegenerative disorder, which results in progressive and permanent deterioration of the nerve cells, engages many teams in the development of new treatments. One scientific approach states that this disease must be attacked at its earliest possible stage, even before the first symptoms appear, […]
- What's on? - 12.09.2014
World Lymphoma Awareness Day
To mark the 8th World Lymphoma Day in France, the France Lymphome Espoir (France Lymphoma Hope) association is conducting a tour of eight large cities in France from 15 to 25 September. Patients, those close to them, and caregivers are thus invited to share their experience on themes such as care and living with the […]
- What's on? - 11.09.2014
2014 World sepsis day : Action against lethal infections
In partnership with Inserm, the Institut Pasteur is organising the first french edition of World Sepsis Day this Friday 12 September. Conferences held at this event will be aimed at informing the general public and increasing awareness about these infections. Sepsis (or septicaemia) represents the impact of serious infections on the body’s vital functions. This […]
- Press releases - 11.09.2014
“Immortal” flatworms: a weapon against bacteria
A novel mode of defense against bacteria such as the causal agent of tuberculosis or Staphylococcus aureus has been identified in humans by studying a small, aquatic flatworm, the planarian.
- Press releases - 10.09.2014
Benzodiazepines and Alzheimer’s disease: the risk increases with duration of exposure
Researchers at Inserm Unit 657, “Pharmacoepidemiology and evaluation of the impact of health products on the population,” report new results on the link between benzodiazepines and dementia.
- Press releases - 08.09.2014
Alim Louis Benabid receives the 2014 Lasker Award
The 2014 Lasker Award has just been won by Alim Louis Benabid, Director of Inserm Unit 318 “Preclinical Neurosciences” from 1988 to 2006, and winner of the 2008 Inserm Prix d’Honneur for his work on deep brain stimulation for the treatment of Parkinson’s disease.
- What's on? - 08.09.2014
Alim Louis Benabid receives the 2014 Lasker Award
The 2014 Lasker Award has just been won by Alim Louis Benabid, Director of Inserm Unit 318 “Preclinical Neurosciences” from 1988 to 2006, and winner of the 2008 Inserm Prix d’Honneur for his work on deep brain stimulation for the treatment of Parkinson’s disease.Since 1945, the Lasker Award has distinguished the most brilliant researchers who […]
- Press releases - 02.09.2014
Exposure of pregnant women to certain phenols may disrupt the growth of boys during foetal development and the first years of life
A research consortium bringing together teams from Inserm, the Nancy and Poitiers University Hospitals, and the Centers for Disease Control and Prevention (CDC, Atlanta, USA), and coordinated by the Inserm and University of Grenoble Environmental Epidemiology team (Unit 823), has just published an epidemiological study indicating that exposure to certain phenols during pregnancy, especially parabens and triclosan, may disrupt growth of boys during foetal growth and the first years of life. Bisphenol A was not associated with any definite modification in growth. T
- Press releases - 18.08.2014
From rectal cells to neurons : keys to understanding transdifferentiation
How can a specialized cell change its identity? A team from the Institut de Génétique et de Biologie Moléculaire et Cellulaire (CNRS/INSERM/Université de Strasbourg) investigated a 100% effective natural example of this phenomenon, which is called transdifferentiation. This process, by which some cells lose their characteristics and acquire a new identity, could be more generally […]
- What's on? - 14.08.2014
Use of unapproved treatments against Ebola : what are the ethical issues?
1) Access to experimental treatment, on a compassionate basis, given the severe spontaneous development of the disease (60% mortality). Who is given priority when administering treatment available in small quantities and under what conditions in the absence of human data? In addition, the ZMapp serum is developed by private pharmaceutical companies, which raises the issue […]